Regulation of muscle atrophy in aging and disease

Advances in Experimental Medicine and Biology

Volumn 694, Issue , 2010, Pages 211-233

  Vinciguerra, Manlio ^a   Musaro, Antonio ^b   Rosenthal, Nadia ^b  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY EMBL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATROGIN 1; CALPAIN; CASPASE; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CATHEPSIN L; INTERLEUKIN 6; LENTIVIRUS VECTOR; MUSCLE RING FINGER 1 PROTEIN; PARVOVIRUS VECTOR; PROTEASOME; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; AUTOPHAGY; CELL THERAPY; GENE THERAPY; HEART FAILURE; HUMAN; LYSOSOME; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; MUSCLE FORCE; MUSCLE GROWTH; MUSCLE REGENERATION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

AGING; ANIMALS; HUMANS; MUSCULAR ATROPHY; MUSCULAR DISORDERS, ATROPHIC; SIGNAL TRANSDUCTION;

EID: 78049404627     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-7002-2_15     Document Type: Article

References (185)

1. Baracos V. Hypercatabolism and hypermetabolism in wasting states. Curr Opin Clin Nutr Metab Care 2002; 5(3):237-39. (Pubitemid 40684667)
2. Baracos V. Cancer-associated cachexia and underlying biological mechanisms. Ann Rev Nutr 2006; 26:435-61.
3. Saini A, Faulkner S, Al-Shanti N et al. Powerful signals for weak muscles. Ageing Res Rev 2009; 8(4):251-67.
4. Croall D, Ersfeld K. The calpains: modular designs and functional diversity. Genome Biol 2007; 8(6):218.
5. Cannon J, Meydani SN, Fielding RA et al. Acute phase response in exercise. II. Associations between vitamin E, cytokines and muscle proteolysis. Am J Physiol 1991; 260:R1235-40.
6. Armstrong R, Warren GL, Warren JA. Mechanisms of exercise-induced muscle fibre injury. Sports Med 1991; 12(3):184-207.
7. Murphy R. Calpains, skeletal muscle function and exercise. Clin Exp Pharmacol Physiol 2009. [Epub ahead of print].
8. Sorimachi H, Imajoh-Ohmi S, Emori Y et al. Molecular cloning of a novel mammalian calcium-dependent protease distinct from both m- and mu-types. Specific expression of the mRNA in skeletal muscle. J Biol Chem 1989; 264:20106-11. (Pubitemid 20008132)
9. Huang J, Forsberg NE. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci USA 1998; 95:12100-005.
10. Kumamoto T, Kleese WC, Cong JY et al. Localization of the Ca(2+)-dependent proteinases and their inhibitor in normal, fasted and denervated rat skeletal muscle. Anat Rec 1992; 232:60-77.
11. Saido T, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological- pathological involvement. FASEB J 1994; 8:814-22.
12. Takamure M, Murata KY, Tamada Y et al. Calpain-dependent alpha-fodrin cleavage at the sarcolemma in muscle diseases. Muscle Nerve 2005; 32(3):303-9. (Pubitemid 41232613)
13. Martin S, O'Brien GA, Nishioka WK et al. Proteolysis of fodrin (non-erythroid spectrin) during apoptosis. J Biol Chem 1995; 270:6425-8.
14. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008; 197(1):1-10. (Pubitemid 351566920)
15. Di Lisa F, De Tullio R, Salamino F et al. Specific degradation of troponin T and I by mu-calpain and its modulation by substrate phosphorylation. Biochem J 1995; 308:57-61.
16. Noma H, Kato T, Fujita H et al. Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes. Immunology 2009; 128(1 Suppl):e487-96.
17. Stupka N, Tarnopolsky MA, Yardley NJ et al. Cellular adaptation to repeated eccentric exercise-induced muscle damage. J Appl Physiol 2001; 91(4):1669-78. (Pubitemid 32900358)
18. Kumamoto T, Fujimoto S, Ito T et al. Proteasome expression in the skeletal muscles of patients with muscular dystrophy. Acta Neuropathol 2000; 100(6):595-602.
19. Richard I, Roudaut C, Marchand S et al. Loss of calpain 3 proteolytic activity leads to muscular dystrophy and to apoptosis-associated IkappaBalpha/nuclear factor kappaB pathway perturbation in mice. J Cell Biol 2000; 151(7):1583-90. (Pubitemid 32047605)
20. Baghdiguian S, Martin M, Richard I et al. Calpain 3 deficiency is associated with myonuclear apoptosis and profound perturbation of the IkappaB alpha/NF-kappaB pathway in limb-girdle muscular dystrophy type 2A. Nat Med 1999; 5:503-11. (Pubitemid 29220208)
21. Spencer M, Guyon JR, Sorimachi H et al. Stable expression of calpain 3 from a muscle transgene in vivo: immature muscle in transgenic mice suggests a role for calpain 3 in muscle maturation. Proc Natl Acad Sci USA 2002; 99:8874-9. (Pubitemid 34693651)
22. Tidball J, Wehling-Henricks M. The role of free radicals in the pathophysiology of muscular dystrophy. J Appl Physiol 2007; 102(4):1677-86. (Pubitemid 46571068)
23. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene 2008; 27(48):6194-206.
24. Enari M, Sakahira H, Yokoyama H et al. A caspase-activated DNase that degrades DNA during apoptosis and its inhibitor. Nature 1998; 391:43-50. (Pubitemid 28079208)
25. Lechardeur D, Drzymala L, Sharma M et al. Determinants of the nuclear localization of the heterodimeric DNA fragmentation factor (ICAD/CAD). Oncogene 2000; 150(2):321-34. (Pubitemid 30491356)
26. Liu X, Zou H, Slaughter C et al. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell 1997; 89:175-84. (Pubitemid 27199890)
27. Kivinen K, Kallajoki M, Taimen P. Caspase-3 is required in the apoptotic disintegration of the nuclear matrix. Exp Cell Res 2005; 15(311(1)):62-73. (Pubitemid 41527175)
28. Orth K, Chinnaiyan AM, Garg M et al. The CED-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 1996; 271:16443-6. (Pubitemid 26238991)
29. Takahashi A, Alnemri ES, Lazebnik YA et al. Cleavage of lamin A by Mch2 alpha but not CPP32: multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis. Proc Natl Acad Sci USA 1996; 93:8395-400.
30. Chen F, Chang R, Trivedi M et al. Caspase proteolysis of desmin produces a dominant-negative inhibitor of intermediate filaments and promotes apoptosis. J Biol Chem 2003; 278(9):6848-53. (Pubitemid 36800675)
31. Kothakota S, Azuma T, Reinhard C et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278(5336):294-8. (Pubitemid 27450877)
32. Sandri M, El Meslemani AH, Sandri C et al. Caspase 3 expression correlates with skeletal muscle apoptosisin Duchenne and facioscapulo human muscular dystrophy. A potential target for pharmacological treatment? J Neuropathol Exp Neurol 2001; 60(3):302-12. (Pubitemid 32209649)
33. Hotti A, Järvinen K, Siivola P et al. Caspases and mitochondria in c-Myc-induced apoptosis: identification of ATM as a new target of caspases. Oncogene 2000; 19(19):2354-62. (Pubitemid 30307212)
34. Rhéaume E, Cohen LY, Uhlmann F et al. The large subunit of replication factor C is a substrate for caspase-3 in vitro and is cleaved by a caspase-3-like protease during Fas-mediated apoptosis. EMBO J 1997; 16(21):6346-54. (Pubitemid 27483261)
35. Belizario J, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001; 84:1135-40. (Pubitemid 32448514)
36. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 2008; 23:160-70.
37. Mammucari C, Milan G, Romanello V et al. FoxO3 Controls Autophagy in Skeletal Muscle In Vivo. Cell Metab 2007; 6:458-71. (Pubitemid 350163055)
38. Mammucari C, Schiaffino, S, Sandri M. Downstream of Akt: FoxO3 and mTOR in the regulation of autophagy in skeletal muscle. Autophagy 2008; 4:524-6. (Pubitemid 351705153)
39. Zhao J, Brault JJ, Schild A et al. FoxO3 Coordinately Activates Protein Degradation by the Autophagic/Lysosomal and Proteasomal Pathways in Atrophying Muscle Cells. Cell Metab 2007; 6:472-83. (Pubitemid 350163056)
40. Clarke B, Drujan D, Willis MS et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007; 6:376-85. (Pubitemid 350011998)
41. Cohen S, Brault JJ, Gygi SP et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009; 185:1083-95.
42. Fielitz J, Kim MS, Shelton JM et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 2007; 117:2486-95. (Pubitemid 47494350)
43. Solomon V, Goldberg AL. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996; 271:26690-7. (Pubitemid 26359075)
44. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42.
45. Mizushima N, Levine B, Cuervo AM et al. Autophagy fights disease through cellular self-digestion. Nature 2008; 45:1069-75. (Pubitemid 351317450)
46. Lecker S, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin proteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17:1807-19. (Pubitemid 44036165)
47. Tanida I, Ueno T, Kominami E. Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 2004; 279(47704-47710.). (Pubitemid 39540917)
48. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol 2004; 36:2503-18. (Pubitemid 39119762)
49. McElhinny A, Kakinuma K, Sorimachi H et al. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1. J Cell Biol 2002; 157:125-36. (Pubitemid 34847835)
50. Bodine S, Latres E, Baumhueter S et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294:1704-8. (Pubitemid 33104839)
51. Deval C, Mordier S, Obled C et al. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting. Biochem J 2001; 360:143-50. (Pubitemid 33081958)
52. Lecker S, Jagoe RT, Gilbert A et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18:39-51. (Pubitemid 38076464)
53. Duncan E, Muratore-Schroeder TL, Cook RG et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 2008; 135:284-94.
54. Masiero E, Sandri M. Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 2010; 6(2):[Epub ahead of print].
55. Musaro A, Fulle S, Fano G. Oxidative stress and muscle homeostasis. Curr Opin Clin Nutr Metab Care 2010: Epub ahead of print.
56. Dobrowolny G, Aucello M, Rizzuto E et al. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. Cell Metab 2008; 8(5):425-36.
57. Mitch W, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. New Engl J Med 1996; 335:1897-905. (Pubitemid 26419198)
58. Auclair D, Garrel DR, Chaouki Zerouala A et al. Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol 1997; 272((3 Pt 1)):C1007-16.
59. Llovera M, Garcia-Martinez C, Lopez-Soriano J et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998; 142(1-2):183-9. (Pubitemid 28438290)
60. Argiles JM, Lopez-Soriano FJ. Catabolic proinflammatory cytokines. Curr Opin Clin Nutr Metab Care 1998; 1(3):245-51. (Pubitemid 128539449)
61. Tisdale M. Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2008; 2(4):256-61.
62. Tisdale M. Mechanisms of cancer cachexia. Physiol Rev 2009; 89(2):381-410.
63. Moresi V, Pristera A, Scicchitano BM et al. Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells 2008; 26(4):997-1008.
64. Moresi V, Garcia-Alvarez G, Pristera A et al. Modulation of caspase activity regulates skeletal muscle regeneration and function in response to vasopressin and tumor necrosis factor. PLoS One 2009; 4(5):e5570.
65. Schwarzkopf M, Coletti D, Sassoon D et al. Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes Dev 2006; 20(24):3440-52. (Pubitemid 44969161)
66. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109 Suppl:S81-96.
67. Relaix F, Weng X, Marazzi G et al. Sassoon D. Pw1, a novel zinc finger gene implicated in the myogenic and neuronal lineages. Dev Biol 1996; 177(2):383-96. (Pubitemid 26275892)
68. Relaix F, Wei XJ, Wu X et al. Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway. Nat Genet 1998; 18(3):287-91. (Pubitemid 28117271)
69. Coletti D, Yang E, Marazzi G et al. TNFalpha inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways. EMBO J 1997; 21(4):631-42. (Pubitemid 34174044)
70. Haddad F, Zaldivar F, Cooper DM et al. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98(3):911-7.
71. De Benedetti F, Alonzi T, Moretta A et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 1997; 99(4):643-50. (Pubitemid 27097665)
72. Jimenez-Mallebrera C, Brown SC, Sewry CA et al. Congenital muscular dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005; 62(7-8):809-23. (Pubitemid 40655631)
73. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 2005; 32(1):1-18. (Pubitemid 40917885)
74. Batchelor C, Winder SJ. Sparks, signals and shock absorbers: how dystrophin loss causes muscular dystrophy. Trends Cell Biol 2006; 16(4):198-205.
75. Lapidos K, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004; 94(8):1023-31. (Pubitemid 38579696)
76. Sciandra F, Gawlik KI, Brancaccio A et al. Dystroglycan: a possible mediator for reducing congenital muscular dystrophy? Trends Biotechnol 2007; 25(6):262-8.
77. Sandona D, Betto R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med 2009; 11:e28.
78. Patton B, Wang B, Tarumi YS et al. A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination. J Cell Sci 2008; 121(10):1593-604. (Pubitemid 351911816)
79. Mayer U, Saher G, Fassler R et al. Absence of integrin alpha 7 causes a novel form of muscular dystrophy. Nat Genet 1997; 17:318-23. (Pubitemid 27475996)
80. Rooney J, Welser JV, Dechert MA et al. Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin. J Cell Sci 2006; 119(11):2185-95. (Pubitemid 43960308)
81. Suzuki N, Motohashi N, Uezumi A et al. NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J Clin Invest 2007; 117(9):2468-76. (Pubitemid 47494348)
82. Acharyya S, Butchbach ME, Sahenk Z et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005; 8(5):421-32. (Pubitemid 41579836)
83. Berridge M, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat Rev Mol Cell Biol 2000; 1(1):11-21.
84. Berridge M, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 2003; 4(7):517-29. (Pubitemid 36773404)
85. Berchtold M, Brinkmeier H, Müntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity and disease. Physiol Rev 2000 80(3):1215-65. (Pubitemid 30452014)
86. Hopf F, Turner PR, Steinhardt RA. Calcium misregulation and the pathogenesis of muscular dystrophy. Subcell Biochem 2007; 45:429-64.
87. Acharyya S, Villalta SA, Bakkar N et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007; 117(4):889-901. (Pubitemid 46556745)
88. Blake D, Weir A, Newey SE et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82:291-329. (Pubitemid 34654455)
89. Dudley R, Danialou G, Govindaraju K et al. Sarcolemmal damage in dystrophin deficiency is modulated by synergistic interactions between mechanical and oxidative/nitrosative stresses. Am J Pathol 2006; 168(4):1276-87.
90. Hand C, Rouleau GA. Familial amyotrophic lateral sclerosis. Muscle Nerve 2002; 25(2):135-59. (Pubitemid 34117061)
91. Robert V, Massimino ML, Tosello V et al. Alteration in calcium handling at the subcellular level in mdx myotubes. J Biol Chem 2001; 276(7):4647-51.
92. Shkryl V, Martins AS, Ullrich ND et al. Reciprocal amplification of ROS and Ca(2+) signals in stressed mdx dystrophic skeletal muscle fibers. Pflugers Arch 2009; 458(5):915-28.
93. Turner P, Westwood T, Regen CM et al. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988; 335:735-8.
94. Valentine J, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005; 74:563-93. (Pubitemid 40995518)
95. von Lewinski F, Keller BU. Ca2+, mitochondria and selective motoneuron vulnerability: implications for ALS. Trends Neurosci 2005; 28(9):494-500. (Pubitemid 41187799)
96. Schiaffino S, Sandri M, Murgia M. Activity-dependent signaling pathways controlling muscle diversity and plasticity. Physiology (Bethesda) 2007; 22:269-78.
97. Porter J, Khanna S, Kaminski HJ et al. A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Hum Mol Genet 2002; 11(3):263-72. (Pubitemid 34173355)
98. Evans N, Misyak SA, Robertson JL et al. Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil 2009; 88(6):502-22.
99. Haslett J, Sanoudou D, Kho AT et al. Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci USA 2002; 99(23):15000-5. (Pubitemid 35334599)
100. Peterson J, Guttridge DC. Skeletal muscle diseases, inflammation and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int Rev Immunol 2008; 27(5):375-87.
101. Vetrone S, Montecino-Rodriguez E, Kudryashova E et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest 2009; 119(6):1583-94.
102. Mourkioti F, Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration. Trends Immunol 2005; 26(10):535-42. (Pubitemid 41297684)
103. Tedesco F, Dellavalle A, Diaz-Manera J et al. Repairing skeletal muscle: regenerative potential of skeletal muscle stem cells. J Clin Invest 2010; 120(1):doi: 10.1172/JCI40373.
104. Yan Z, Choi S, Liu X et al. Highly coordinated gene regulation in mouse skeletal muscle regeneration. J Biol Chem 2003; 278:8826-36.
105. Carosio S, Berardinelli MG, Aucello M et al. Impact of ageing on muscle cell regeneration. Ageing Res Rev 2009. [Epub ahead of print].
106. Cohn R, Henry MD, Michele DE et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 2002; 110:639-48. (Pubitemid 35247843)
107. Shi X, Garry DJ. Muscle stem cells in development, regeneration and disease. Genes Dev 2006; 20(13):1692-708. (Pubitemid 43992877)
108. Musaro A, McCullagh K, Paul A et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 2001; 27(2):195-200. (Pubitemid 32157448)
109. Conboy IM, Conboy MJ, Wagers AJ et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 2005; 433(7027):760-4. (Pubitemid 40292986)
110. Karalaki M, Fili S, Philippou A et al. Muscle regeneration: cellular and molecular events. In Vivo 2009; 23(5):779-96.
111. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 2007; 7(3):310-5. (Pubitemid 46738500)
112. Kollias H, McDermott JC. Transforming growth factor-beta and myostatin signaling in skeletal muscle.J Appl Physiol 2008; 104(3):579-87.
113. Mozzetta C, Minetti G, Puri PL. Regenerative pharmacology in the treatment of genetic diseases: the paradigm of muscular dystrophy. Int J Biochem Cell Biol 2009; 41(4):701-10.
114. Patel K, Amthor H. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle. Neuromuscul Disord 2005; 15(2):117-26. (Pubitemid 40202738)
115. Roth S, Walsh S. Myostatin: a therapeutic target for skeletal muscle wasting. Curr Opin Clin Nutr Metab Care 2004; 7(3):259-63. (Pubitemid 40340662)
116. Bogdanovich S, Krag TO, Barton ER et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420(6914):418-21. (Pubitemid 35415652)
117. Nakatani M, Takehara Y, Sugino H et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J 2008; 22(2):477-87. (Pubitemid 351225584)
118. Siriett V, Salerno MS, Berry C et al. Antagonism of myostatin enhances muscle regeneration during sarcopenia. Mol Ther 2007; 15(8):1463-70. (Pubitemid 47099303)
119. Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 2008; 37(3):308-16. (Pubitemid 351304790)
120. Sumner C, Wee CD, Warsing LC et al. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet 2009; 18(17):3145-52.
121. Mourkioti F, Kratsios P, Luedde T et al. Targeted ablation of IKK2 improves skeletal muscle strength, maintains mass and promotes regeneration. J Clin Invest 2006; 116(11):2945-54. (Pubitemid 44684479)
122. Mourkioti F, Rosenthal N. NF-kappaB signaling in skeletal muscle: prospects for intervention in muscle diseases. J Mol Med 2008; 86(7):747-59.
123. Gregorevic P, Hayes A, Lynch GS et al. Functional properties of regenerating skeletal muscle following LIF administration. Muscle Nerve 2000; 23(10):1586-8.
124. Pedersen B, Steensberg A, Keller P et al. Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Pflugers Arch 2003; 446(1):9-16. (Pubitemid 36539527)
125. Pedersen B. IL-6 signalling in exercise and disease. Biochem Soc Trans 2007; 35(5):1295-7. (Pubitemid 350206483)
126. White J, Bower JJ, Kurek JB et al. Leukemia inhibitory factor enhances regeneration in skeletal muscles after myoblast transplantation. Muscle Nerve 2001; 24(5):695-7. (Pubitemid 32373033)
127. White J, Davies M, McGeachie J et al. An evaluation of leukaemia inhibitory factor as a potential therapeutic agent in the treatment of muscle disease. Neuromuscul Disord 2002; 12(10):909-16. (Pubitemid 35408672)
128. Pistilli E, Siu PM, Alway SE. Interleukin-15 responses to aging and unloading-induced skeletal muscle atrophy. Am J Physiol Cell Physiol 2007; 292(4):C1298-304. (Pubitemid 46631721)
129. Saidenberg-Kermanac'h N, Bessis N, Deleuze V et al. Efficacy of interleukin-10 gene electrotransfer into skeletal muscle in mice with collagen-induced arthritis. J Gene Med 2003; 5:164-71. (Pubitemid 40309693)
130. Wehling M, Spencer MJ, Tidball JG. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol 2001; 155(1):123-31. (Pubitemid 34286213)
131. Colussi C, Mozzetta C, Gurtner A et al. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc Natl Acad Sci USA 2008; 105(49):19183-7.
132. Colussi C, Mozzetta C, Gurtner A et al. Nitric oxide deficiency determines global chromatin changes in Duchenne muscular dystrophy. FASEB J 2009; 23(7):2131-41.
133. Coleman M, DeMayo F, Yin KC et al. Myogenic vector expression of insulin-like growth factor Istimulates muscle cell differentiation and myofiber hypertrophy in transgenic mice. J Biol Chem 1995; 270:12109-16.
134. Liu JP, Baker J, Perkins AS et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75(1):59-72. (Pubitemid 23306021)
135. Pelosi L, Giacinti C, Nardis C et al. Local expression of IGF-1 accelerates muscle regeneration by rapidlymodulating inflammatory cytokines and chemokines. FASEB J 2007; 21(7):1393-402. (Pubitemid 46684842)
136. Grounds M. Reasons for the degeneration of ageing skeletal muscle: a central role for IGF-1 signalling. Biogerontology 2002; 3:19-24. (Pubitemid 34284971)
137. Rudman D, Kutner MH, Rogers CM et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67:1361-69. (Pubitemid 11099350)
138. Vanitallie T. Frailty in the elderly: contributions of sarcopenia and visceral protein depletion. Metabolism 2003; 52(10 Suppl 2):22-6.
139. Clavel S, Coldefy AS, Kurkdjian E et al. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech Ageing Dev 2006; 127(10):794-801. (Pubitemid 44374662)
140. Belfiore A, Frasca F, Pandini G et al. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30(6):586-623.
141. Powell-Braxton L, Hollingshead P, Warburton C et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993; 7(12B):2609-17. (Pubitemid 24021017)
142. Sutter N, Bustamante CD, Chase K et al. A single IGF1 allele is a major determinant of small size in dogs. Science 2007; 316(5821):112-5. (Pubitemid 46559530)
143. LeRoith D, Roberts, CT Jr. Insulin-like growth factor I (IGF-I): a molecular basis for endocrine versus local action? Mol Cell Endocrinol 1991; 77:C57-61.
144. Winn N, Paul A, Musaro A et al. Insulin-like growth factor isoforms in skeletal muscle aging, regeneration and disease. Cold Spring Harb Symp Quant Biol 2002; 67:507-18. (Pubitemid 36775547)
145. Shavlakadze T, Winn N, Rosenthal N et al. Reconciling data from transgenic mice that overexpress IGF-I specifically in skeletal muscle. Growth Horm IGF Res 2005; 15(1):4-18. (Pubitemid 40220850)
146. Bach M, Roberts CT Jr, Smith EP et al. Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol Endocrinol 1990; 4:899-904.
147. Pfeffer L, Brisson BK, Lei H et al. The insulin-like growth factor (IGF)-I E-peptides modulate cell entry of the mature IGF-I protein. Mol Biol Cell 2009; 20(17):3810-7.
148. Barton E. Viral expression of insulin-like growth factor-I isoforms promotes different responses in skeletal muscle. J Appl Physiol 2006; 100(6):1778-84. (Pubitemid 43845850)
149. Matheny RJ, Nindl BC, Adamo ML. Minireview: Mechano-Growth Factor: A Putative Product of IGF-I Gene Expression Involved in Tissue Repair and Regeneration. Endocrinology 2010. [Epub ahead of print].
150. Stitt TN, Drujan D, Clarke BA et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14(3):395-403. (Pubitemid 38591410)
151. Shavlakadze T, Boswell JM, Burt DW et al. Rskalpha-actin/hIGF-1 transgenic mice with increased IGF-I in skeletal muscle and blood: impact on regeneration, denervation and muscular dystrophy. Growth Horm IGF Res 2006; 16(3):157-73. (Pubitemid 44103479)
152. Lara-Pezzi E, Winn N, Paul A et al. A naturally occurring calcineurin variant inhibits FoxO activity and enhances skeletal muscle regeneration. J Cell Biol 2007; 179(6):1205-18. (Pubitemid 350277739)
153. Musaro A, Giacinti C, Borsellino G et al. Stem cell-mediated muscle regeneration is enhanced by localisoform of insulin-like growth factor 1. Proc Natl Acad Sci USA 2004; 101(5):1206-10. (Pubitemid 38182667)
154. Barton E, Morris L, Musaro A et al. Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol 2002; 157(1):137-48.
155. Schulze P, Fang J, Kassik KA et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005; 97(5):418-26. (Pubitemid 41298171)
156. Song Y, Li Y, Du J et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115(2):451-8. (Pubitemid 40385487)
157. Barton E, Demeo J, Lei H. The insulin-like growth factor (IGF)-1 E-peptides are required for isoform specific gene expression and muscle hypertrophy after local IGF-1 production. J Appl Physiol 2010.
158. Song Y, Godard M, Li Y et al. Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J Investig Med 2005; 53(3):135-42. (Pubitemid 40705798)
159. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8:915-28.
160. Florini J, Ewton DZ, Coolican SA. Growth hormone and the insulin-like growth factor system in myogenesis. Endocr Rev 1996; 17(5):481-517. (Pubitemid 26346639)
161. Nelson S, Crosbie RH, Miceli MC et al. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009; 22(5):532-8.
162. Tang Y, Cummins J, Huard J et al. AAV-directed muscular dystrophy gene
163. Trollet C, Athanasopoulos T, Popplewell L et al. Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 2009; 9(7):849-66.
164. Nanou A, Azzouz M. Gene therapy for neurodegenerative diseases based on lentiviral vectors. Prog Brain Res 2009; 175:187-200.
165. Azzouz M, Le T, Ralph GS et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004; 114(12):1726-31. (Pubitemid 40385528)
166. Hojman P, Gissel H, Andre F et al. Physiological effects of high and low voltage pulse combinations for gene electrotransfer in muscle. Hum Gen Ther 2008. [Epub ahead of print].
167. Zampaglione I, Arcuri M, Cappelletti M et al. In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters. J Gene Med 2005; 7(11):1475-81. (Pubitemid 41672406)
168. Barton-Davis E, Shoturma DI, Musaro A et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. Proc Natl Acad Sci USA 1998; 95(26):15603-7. (Pubitemid 29018746)
169. Liu Z, Wu Y, Chen BG. Myoblast therapy: from bench to bedside. Cell Transplant 2006; 15(6):455-62. (Pubitemid 44655936)
170. Menasché P. Skeletal myoblasts and cardiac repair. J Mol Cell Cardiol 2008; 45(4):545-53.
171. Smythe G, Hodgetts SI, Grounds MD. Problems and solutions in myoblast transfer therapy. J Cell Mol Med 2001; 5(1):33-47. (Pubitemid 33772982)
172. Skuk D, Tremblay JP. Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. J Muscle Res Cell Motil 2003; 24(4-6):285-300. (Pubitemid 37323636)
173. Camirand G, Caron NJ, Asselin I et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. Transplantation 2001; 72(1):38-44. (Pubitemid 32652504)
174. Kinoshita I, Roy R, Dugré FJ et al. Myoblast transplantation in monkeys: control of immune response by FK506. J Neuropathol Exp Neurol 1996; 55(6):687-97. (Pubitemid 26187395)
175. Skuk D, Goulet M, Roy B et al. Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 2000; 59(3):197-206. (Pubitemid 30143878)
176. Tremblay J, Skuk D, Palmieri B et al. A case for immunosuppression for myoblast transplantation in duchenne muscular dystrophy. Mol Ther 2009; 17(7):1122-4.
177. McKinney-Freeman SL, Jackson KA, Camargo FD et al. Muscle-derived hematopoietic stem cells are hematopoietic in origin. Proc Natl Acad Sci USA 2002; 99:1341-6. (Pubitemid 34136495)
178. Bhagavati S. Stem cell based therapy for skeletal muscle diseases. Curr Stem Cell Res Ther 2008; 3(3):219-28.
179. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279(5356):1528-30. (Pubitemid 28217075)
180. Ferrari G, Stornaiuolo A, Mavilio F. Failure to correct murine muscular dystrophy. Nature 2001; 411:1014-5. (Pubitemid 32612316)
181. LaBarge M, Blau HM. Biological progression from adult bone marrow to mononucleate muscle stem cell to multinucleate muscle fiber in response to injury. Cell 2002; 111:589-601. (Pubitemid 35356563)
182. Blau H, Brazelton TR, Weimann JM. The evolving concept of a stem cell: entity or function? Cell 2001; 105(7):829-41. (Pubitemid 32635085)
183. Corbel S, Lee A, Yi L et al. Contribution of hematopoietic stem cells to skeletal muscle. Nat Med 2003; 9(12):1528-32. (Pubitemid 38004781)
184. Rudnicki M. Marrow to muscle, fission versus fusion. Nat Med 2003; 9(12):1461-2. (Pubitemid 38004768)
185. Morgan JE, Gross JG, Pagel CN et al. Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site. J Cell Biol 2002; 157:693-702. (Pubitemid 34839796)